Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

12.45CNY
25 Sep 2017
Change (% chg)

¥0.35 (+2.89%)
Prev Close
¥12.10
Open
¥12.10
Day's High
¥12.51
Day's Low
¥12.05
Volume
7,369,552
Avg. Vol
4,570,193
52-wk High
¥15.08
52-wk Low
¥10.24

Chart for

About

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infec... (more)

Overall

Beta: 1.17
Market Cap(Mil.): ¥11,682.94
Shares Outstanding(Mil.): 965.53
Dividend: 0.05
Yield (%): 0.41

Financials

  Industry Sector
P/E (TTM): -- 30.87 15.95
EPS (TTM): -- -- --
ROI: -- 14.31 15.19
ROE: -- 15.61 13.87

BRIEF-Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval

* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration

Sep 11 2017

BRIEF-Zhejiang Hisun Pharma cuts share issue size

* Says it cuts share issue size to 940.92 million yuan ($142.72 million) from 1.17 billion yuan previously

Aug 30 2017

BRIEF- Zhejiang Hisun Pharmaceutical to set up pharmaceutical unit in Zhejiang

* Says it plans to set up a wholly owned pharmaceutical unit in Zhejiang, with registered capital of 10 million yuan

Aug 10 2017

BRIEF-Zhejiang Hisun Pharmaceutical to pay FY 2016 annual div on July 7

* Says it will pay FY 2016 dividend to shareholders of record on July 6

Jun 30 2017

BRIEF-Zhejiang Hisun Pharmaceutical receives GMP certificate

* Says it received goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration

Jun 28 2017

BRIEF-Zhejiang Hisun Pharmaceutical receives administrative order

* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report

Apr 25 2017

BRIEF-Zhejiang Hisun Pharmaceutical amends FY 2016 net profit outlook

* Says in the previous outlook, the company expected the net profit for FY 2016 to increase by 260 percent to 300 percent

Mar 29 2017

Earnings vs. Estimates